济南哪有生殖医院济南有菌前列腺炎的治疗,济南我的下面硬不起来了怎么办,济南提高持久力的办法,济南怎能治早泄,济南患有早泄怎么治疗,济南勃起中途疲软怎么调理,济南男子房事不行怎么办

WASHINGTON, March 22 (Xinhua) -- A long-term study by Greek researchers has shown the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous (self) stem cells in treating people with aggressive forms of multiple sclerosis (MS).The study was published on Tuesday in Neurology, the medical journal of the American Academy of Neurology.For the treatment, chemotherapy drugs are used to kill all of the patient's blood cells, including the immune cells that are believed to be attacking the body's own central nervous system. Bone marrow stem cells removed from the patient are purified and transplanted back into the body, which saves life by replacing the blood cells and also is proposed to "reboot" the immune system.A human embryonic stem cell line derived at Stanford University is seen in this handout photo released to Reuters by the California Institute for Regenerative Medicine, March 9, 2009The study followed 35 people for an average of 11 years after transplant. The study involved people with rapidly progressive MS who had tried a number of other treatments for MS with little or no effect. All were severely disabled by the disease, with an average score of six on a scale of disease activity that ranges from zero being a normal neurological examination to 10 meaning death due to MS.A score of six means able to walk with a cane or crutch; a seven is mainly in a wheelchair. All had worsened by at least one point on the scale in the year prior to the transplant.After the transplants, the probability of participants having no worsening of their disease for 15 years was 25 percent. The probability was higher -- 44 percent -- for those who had active brain lesions, which are a sign of disease activity, at the time of the transplant.For 16 people, symptoms improved by an average of one point on the scale after the transplant, and the improvements lasted for an average of two years. The participants also had a reduction in the number and size of lesions in their brains. Two people (six percent) died from complications related to the transplant at two months and 2-1/2 years post-transplant.Study author Vasilios Kimiskidis, of Aristotle University in Thessaloniki, Greece, noted that more research is needed on this treatment, including studies that compare people receiving the treatment to a control group that does not receive the treatment."Keeping that in mind, our feeling is that stem cell transplants may benefit people with rapidly progressive MS," he said. "This is not a therapy for the general population of people with MS but should be reserved for aggressive cases that are still in the inflammatory phase of the disease."

BEIJING, March 27 (Xinhua) -- China's search giant Baidu has pledged to remove all unauthorized literary works from its free online literary database Wenku within three days.After receiving requests from copyright owners to remove their works, Baidu has sped up its process of checking for unauthorized items. The unauthorized works were uploaded by Internet users to Wenku without prior approval from the authors, a spokesman for the Chinese search engine giant said in a statement.In the statement issued Saturday, Baidu apologized for what has "hurt the feelings of a certain number of writers" during Wenku's previous stage of operation, according to a report published Sunday by daily newspaper The Beijing News.Baidu said it respects copyright laws and will continue to cooperate with publishers and writers to establish a revenue-sharing model that will ensure that copyright owners receive a share of revenues from online versions of their works.Hailing Baidu's move to remove the unauthorized works, Wang Yefei, deputy head of Beijing Municipal Bureau of Copyrights hopes that Baidu and the publishers should work together to find win-win methods of mutual cooperation, according to the newspaper.However, some writers involved in the copyright row are dissatisfied with remedies Baidu has so far taken.Shen Haobo, CEO of Beijing Motie Book Co. Ltd, one of the six negotiators representing writers in Thursday's negotiations, told the Beijing Youth Daily that Baidu apologized only because of public pressure, but it did not mean to alter its current operation model for Wenku."Without changes in the operation model, the unauthorized works, even if removed now, could be uploaded again sometime later. Besides, it's unacceptable that Baidu reiterated that it had not infringed on our copyright," Shen was quoted as saying.Popular writer and blogger Han Han posted an open letter he wrote to Baidu's CEO Li Yanhong in his blog, indicating that he might take further actions to uphold his rights if Baidu's stance remains unchanged.Baidu's online literary database Wenku is an open platform for online resource sharing. It has been in operation since 2009.More than 40 Chinese writers posted an open letter online on March 15, accusing Baidu of stealing their works and infringing on their copyrights. Baidu's Wenku database was blamed for allowing literary works to become available online without the authors' prior approval.Baidu was asked to make a public apology, compensate for the writers' losses and halt any cases of copyright infringement.

LOS ANGELES, April 14 (Xinhua) -- Customer complaints of an "uncharacteristic odor" prompted Johnson & Johnson to recall about 57,000 bottles of the prescription anti-seizure drug, Johnson & Johnson announced on Thursday.The recall affects two lots of the Topamax 100 mg tablets made by the company's Ortho-McNeil Neurologics division, Johnson & Johnson said.The drug was shipped and distributed between Oct. 19, 2010 and Dec. 28, 2010 in the United States and Puerto Rico.There were four consumer complaints about an odor believed to be caused by trace amounts of the chemical TBA (2,4,6 tribromoanisole), which is applied to wooden pallets used to transport and store packaging materials, Johnson & Johnson said.The recall is not expected to lead to a product shortage at the market, Ortho-McNeil Neurologics said.Similar complaints of a moldy, musty odor have led to the recalls of millions of bottles of Tylenol, Motrin and Benadryl products earlier.Last month, the U.S. government said it was taking over three Tylenol plants operated by McNeil, and the Food and Drug Administration launched a criminal investigation into safety issues at the factories, CNN reported.

BEIJING, April 19 (Xinhuanet) -- The case in the Hollywood blockbuster "The Social Network" continues in real life.Twins Cameron and Tyler Winklevoss on Monday filed another appeal against their Harvard classmate and Facebook founder Mark Zuckerberg.The Winklevosses claim that the case needs to be reviewed by a special 11-judge panel in the latest appeal, after a three-judge panel of the 9th U.S. Circuit Court of Appeals ruled against the brothers last week.The twins initially claimed that Zuckerberg had stolen their idea for the website but agreed to drop their lawsuit in 2008 in exchange for 20 million dollars in cash and stock in the company.But later they discovered the stock was worth less than claimed at the time and sought to have the deal voided, the brothers said.

NICOSIA, March 8 (Xinhua) -- Cypriot geneticists have reported a non-invasive Down's Syndrome test that could possibly replace the risky amniocentesis procedure now in use.A team of researchers at the Cyprus Institute of Neurology and Genetics reported in Nature Medicine journal that the new test involves only a small quantity of blood taken from the mother's arm, which is analyzed to detect DNA differences between the mother and the fetus.Philippos Patsalis, medical director of the institute, said Tuesday the new method eliminates dangers involved with amniocentesis testing, which involves sampling amniotic fluid by inserting a hollow needle into the mother's uterus.At present, only women belonging to high risk groups, including older women, are tested for Down's Syndrome, which is the most common genetic cause of mental retardation.Patsalis, who led the study, said the new method would be made available to the medical community after clinical tests are concluded world-wide on 1,000 women within two years.